March 31, 2016
The Japan unit of Janssen Pharmaceuticals filed an application on March 30 seeking approval of its anti-IL-12/23 p40 human monoclonal antibody Stelara (ustekinumab) for the treatment of moderate to severe active Crohn’s disease. The treatment of Crohn’s disease with Stelara...read more